Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

SH-110 receives FDA orphan drug designation for the treatment of Glioma

July 22nd 2025

Read More

Cure Today Logo

FDA Grants Orphan Status to Liquid Glioma Treatment SH-110

July 18th 2025

Read More

Oncology Live Logo

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 17th 2025July 16th 2025

Read More

AMERICAN PHARMACEUTICAL REVIEW LOGO

Oral Liquid for Brain Cancer Gets FDA Fast Track Designation

July 17th 2025July 16th 2025

Read More

FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

July 17th 2025July 16th 2025

Read More

BW

SH-110 Receives FDA Orphan Drug Designation for Rare Brain Cancer

July 17th 2025July 16th 2025

Read More

ATOPP

Shorla Oncology Attends ATOPP Summit 2025

July 17th 2025July 9th 2025

Read More

National Oncology Conference Logo

Shorla Oncology Attends 2025 Cardinal Health™ NOC

July 17th 2025June 29th 2025

Read More

YPO Features Sharon

Sharon Cunningham Featured by YPO for Driving Innovation in Oncology

July 17th 2025June 9th 2025

Read More

Older posts
Page1 Page2 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.